# Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer

> **NCT00571740** · PHASE2 · WITHDRAWN · sponsor: **Alliance for Clinical Trials in Oncology**

## Conditions studied

- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **BIOLOGICAL:** cetuximab
- **DRUG:** fluorouracil
- **DRUG:** leucovorin calcium
- **DRUG:** oxaliplatin

## Key facts

- **NCT ID:** NCT00571740
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study was not activated
- **Last updated:** 2016-07-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00571740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00571740, "Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00571740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*